Hadean Ventures

Gesynta Pharma is a clinical-stage pharmaceutical company developing compounds that inhibit the pro-inflammatory enzyme mPGES-1. Its lead drug candidate, vipoglanstat (GS-248), is in development for endometriosis, a prevalent chronic inflammatory disease affecting women's health. Gesynta Pharma also has another drug candidate, GS-073, ready to enter clinical phase I trials.

SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

Alex Therapeutics is a Stockholm-based company developing AI-driven software medical devices (Class I) apps to support clinicians in helping patients change unwanted habits leading to poor medical outcomes. Their evidence-based digital interventions cover areas such as obesity, breast cancer treatment, and nicotine addiction.

Alex Therapeutics is a Stockholm-based company developing AI-driven software medical devices (Class I) apps to support clinicians in helping patients change unwanted habits leading to poor medical outcomes. Their evidence-based digital interventions cover areas such as obesity, breast cancer treatment, and nicotine addiction.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

Founded in Vienna, Austria in 2018, Ribbon Biolabs specializes in the synthesis and exploration of long DNA molecules. The company sets new standards in molecular biology by developing innovative methods for DNA synthesis, enabling breakthroughs in synthetic biology.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Oncoinvent specializes in developing innovative cancer treatments. It focuses on a technology platform that uses radionuclides to deliver targeted alpha radiation therapy, aiming to destroy cancer cells while minimizing harm to surrounding healthy tissue.

SAGA Diagnostics AB is a Swedish company specializing in personalized cancer diagnostics and disease monitoring through molecular genetic analyses, focusing on circulating tumor DNA (ctDNA). Founded in 2016 as a spin-out from a research group at Lund University, SAGA aims to enhance precision cancer medicine and improve patient survival rates with its minimally-invasive liquid biopsy testing services. The company provides a range of services, including gene mutation analysis and treatment monitoring, utilizing advanced technologies such as massively parallel sequencing. SAGA's proprietary tests enable oncologists and biopharmaceutical companies to detect actionable mutations, stratify patient groups, and monitor treatment responses with high sensitivity, thereby contributing significantly to advancements in cancer research and clinical diagnostics.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

CardioMech develops therapeutic devices for structural heart disease. Its flagship technology offers a transcatheter alternative to cardiac surgery for the placement of artificial chords in the mitral valve, enabling surgeons to treat patients with severe, symptomatic degenerative mitral regurgitation.

Gesynta Pharma is a clinical-stage pharmaceutical company developing compounds that inhibit the pro-inflammatory enzyme mPGES-1. Its lead drug candidate, vipoglanstat (GS-248), is in development for endometriosis, a prevalent chronic inflammatory disease affecting women's health. Gesynta Pharma also has another drug candidate, GS-073, ready to enter clinical phase I trials.

Oncoinvent specializes in developing innovative cancer treatments. It focuses on a technology platform that uses radionuclides to deliver targeted alpha radiation therapy, aiming to destroy cancer cells while minimizing harm to surrounding healthy tissue.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Abliva AB is a Swedish pharmaceutical company focused on the research and development of treatments for primary mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria. The company's pipeline includes KL1333, currently in phase I clinical trials, and NV354, an energy replacement therapy that is preparing for clinical trials. KL1333 is noted for its role as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury. Established in 2000 and headquartered in Lund, Sweden, Abliva has formed collaborations with various institutions, enhancing its research capabilities and clinical development efforts.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

SAGA Diagnostics AB is a Swedish company specializing in personalized cancer diagnostics and disease monitoring through molecular genetic analyses, focusing on circulating tumor DNA (ctDNA). Founded in 2016 as a spin-out from a research group at Lund University, SAGA aims to enhance precision cancer medicine and improve patient survival rates with its minimally-invasive liquid biopsy testing services. The company provides a range of services, including gene mutation analysis and treatment monitoring, utilizing advanced technologies such as massively parallel sequencing. SAGA's proprietary tests enable oncologists and biopharmaceutical companies to detect actionable mutations, stratify patient groups, and monitor treatment responses with high sensitivity, thereby contributing significantly to advancements in cancer research and clinical diagnostics.

Nisonic is a medical technology company focused on developing innovative products for the non-invasive diagnosis and monitoring of increased intracranial pressure (ICP). The company's advanced ultrasound technology utilizes an optimized transducer for transorbital imaging and employs machine-learning algorithms to provide automatic measurements and guidance for accurate probe positioning. This approach enables medical professionals in emergency departments, intensive care units, and critical care settings to detect ICP early and intervene effectively, thereby reducing the reliance on invasive methods that carry risks of complications and are limited to larger hospitals. By integrating their software with existing ultrasound devices, Nisonic aims to enhance the accessibility and cost-effectiveness of ICP monitoring, ultimately improving patient outcomes and lowering mortality and disability rates associated with elevated intracranial pressure.

Attgeno is a pharmaceutical company focused on developing innovative treatments for acute life-threatening conditions. The company's primary offering is a nitric oxide-donating drug that aims to address acute pulmonary hypertension by selectively lowering blood pressure in the lungs. This drug utilizes unique nitric oxide-containing compounds that effectively penetrate the bloodstream and facilitate the dilation of blood vessels in the lungs. By enabling the extension of these blood vessels, Attgeno's treatment aims to provide healthcare professionals with a critical tool to manage and alleviate the serious risks associated with elevated lung pressure in patients.